Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial
Russell K. Pachynski
Nature Communications, Published online: 08 May 2026; doi:10.1038/s41467-026-72242-w CheckMate 650 was a multicohort phase 2 trial designed to study the safety and clinical activity of nivolumab plus ipilimumab combination therapy in patients with metastatic castration-resistant prostate cancer. Here the authors report the results of the randomized portion of the trial, including three different immunotherapy treatment cohorts and a current standard-of-care chemotherapy cohort (cabazitaxel).